FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385800132> ?p ?o ?g. }

• W4385800132 endingPage "5840" @default.
• W4385800132 startingPage "5834" @default.
• W4385800132 abstract "To evaluate immunogenicity and safety of heterologous COVID-19 primary vaccination regimens of CoronaVac with fractional and standard BNT162b2 dosages in 5–11-year-old Thai children. This prospective, multicenter, double-blind, randomized control trial divided participants 1:1:1:1 to receive a second dose of either standard (10-μg) or half-dose (5-μg) BNT162b2 vaccines as follows: CoronaVac/10-μg-BNT162b2 (Group 1), CoronaVac/5-μg-BNT162b2 (Group 2), 10-μg-BNT162b2/10-μg-BNT162b2 (Group 3), or 10-μg-BNT162b2/5-μg-BNT162b2 (Group 4). A subset of participants from each arm received 10-μg-BNT162b2 booster (third) doses 16 weeks after their second vaccination. Humoral and cellular immunogenicity were assessed and adverse events (AEs) digitally self-reported. Of 553 enrolled participants, 50 % were male, the median (interquartile range) age was 8.65 (7.00, 10.00) years, and a majority (91 %) had normal weight-for-height. All participants exhibited similarly robust neutralizing antibodies (NAb) against the ancestral Wuhan strain two weeks after the second vaccination, with titers highest in Group 1 (737.60, 95% CI [654.80, 830.88]), followed by Groups 3 (630.42, 95% CI [555.50, 715.45]), 2 (593.98, 95% CI [506.02, 697.23]), and 4 (451.79, 95% CI [388.62, 525.23]), as well as 56.01 % and 49.68 % seroconversion for BA.1 and BA.5, respectively. Half-dose BNT162b2 as a second dose induced significantly lower NAb titers compared to their respective full-dose regimens (p = 0.03 for Groups 1 vs 2 and p < 0.001 for Groups 3 vs 4). 77.71 % of participants developed SARS-CoV-2 ancestral spike protein-specific T-cell responses two weeks after the second vaccination. This was similar across arms. Booster doses generated NAb titers 5.69–11.51-folds higher than the second vaccination against BA.1. AEs were similar across arms, all mild or moderate, and fully resolved 2–3 days thereafter. Standard and fractional heterologous regimens of CoronaVac-BNT162b2 induced similar or higher humoral immunity than homologous BNT162b2 and represent alternative vaccine regimens for children. These findings are highly relevant in settings concurrently using both vaccines." @default.
• W4385800132 created "2023-08-15" @default.
• W4385800132 creator A5005148781 @default.
• W4385800132 creator A5009499406 @default.
• W4385800132 creator A5019617997 @default.
• W4385800132 creator A5022084581 @default.
• W4385800132 creator A5023591398 @default.
• W4385800132 creator A5029953945 @default.
• W4385800132 creator A5035865634 @default.
• W4385800132 creator A5042729323 @default.
• W4385800132 creator A5046064598 @default.
• W4385800132 creator A5049112258 @default.
• W4385800132 creator A5056083261 @default.
• W4385800132 creator A5059440499 @default.
• W4385800132 creator A5064039277 @default.
• W4385800132 creator A5070401547 @default.
• W4385800132 creator A5070748655 @default.
• W4385800132 creator A5077485467 @default.
• W4385800132 creator A5077564500 @default.
• W4385800132 creator A5078158945 @default.
• W4385800132 creator A5091849647 @default.
• W4385800132 date "2023-09-01" @default.
• W4385800132 modified "2023-09-25" @default.
• W4385800132 title "Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5–11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial" @default.
• W4385800132 cites W3173690790 @default.
• W4385800132 cites W3178327314 @default.
• W4385800132 cites W3189762432 @default.
• W4385800132 cites W3189962012 @default.
• W4385800132 cites W3193005084 @default.
• W4385800132 cites W3202964367 @default.
• W4385800132 cites W3212487860 @default.
• W4385800132 cites W3214683919 @default.
• W4385800132 cites W4200320281 @default.
• W4385800132 cites W4206675538 @default.
• W4385800132 cites W4207051048 @default.
• W4385800132 cites W4210307644 @default.
• W4385800132 cites W4210844692 @default.
• W4385800132 cites W4226221011 @default.
• W4385800132 cites W4226343533 @default.
• W4385800132 cites W4284885723 @default.
• W4385800132 cites W4295435192 @default.
• W4385800132 cites W4297534234 @default.
• W4385800132 cites W4302288184 @default.
• W4385800132 cites W4306839895 @default.
• W4385800132 doi "https://doi.org/10.1016/j.vaccine.2023.08.021" @default.
• W4385800132 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37586956" @default.
• W4385800132 hasPublicationYear "2023" @default.
• W4385800132 type Work @default.
• W4385800132 citedByCount "0" @default.
• W4385800132 crossrefType "journal-article" @default.
• W4385800132 hasAuthorship W4385800132A5005148781 @default.
• W4385800132 hasAuthorship W4385800132A5009499406 @default.
• W4385800132 hasAuthorship W4385800132A5019617997 @default.
• W4385800132 hasAuthorship W4385800132A5022084581 @default.
• W4385800132 hasAuthorship W4385800132A5023591398 @default.
• W4385800132 hasAuthorship W4385800132A5029953945 @default.
• W4385800132 hasAuthorship W4385800132A5035865634 @default.
• W4385800132 hasAuthorship W4385800132A5042729323 @default.
• W4385800132 hasAuthorship W4385800132A5046064598 @default.
• W4385800132 hasAuthorship W4385800132A5049112258 @default.
• W4385800132 hasAuthorship W4385800132A5056083261 @default.
• W4385800132 hasAuthorship W4385800132A5059440499 @default.
• W4385800132 hasAuthorship W4385800132A5064039277 @default.
• W4385800132 hasAuthorship W4385800132A5070401547 @default.
• W4385800132 hasAuthorship W4385800132A5070748655 @default.
• W4385800132 hasAuthorship W4385800132A5077485467 @default.
• W4385800132 hasAuthorship W4385800132A5077564500 @default.
• W4385800132 hasAuthorship W4385800132A5078158945 @default.
• W4385800132 hasAuthorship W4385800132A5091849647 @default.
• W4385800132 hasBestOaLocation W43858001321 @default.
• W4385800132 hasConcept C126322002 @default.
• W4385800132 hasConcept C159654299 @default.
• W4385800132 hasConcept C168563851 @default.
• W4385800132 hasConcept C187212893 @default.
• W4385800132 hasConcept C197934379 @default.
• W4385800132 hasConcept C203014093 @default.
• W4385800132 hasConcept C22070199 @default.
• W4385800132 hasConcept C2777451964 @default.
• W4385800132 hasConcept C2777704310 @default.
• W4385800132 hasConcept C2780868878 @default.
• W4385800132 hasConcept C32611913 @default.
• W4385800132 hasConcept C535046627 @default.
• W4385800132 hasConcept C71924100 @default.
• W4385800132 hasConceptScore W4385800132C126322002 @default.
• W4385800132 hasConceptScore W4385800132C159654299 @default.
• W4385800132 hasConceptScore W4385800132C168563851 @default.
• W4385800132 hasConceptScore W4385800132C187212893 @default.
• W4385800132 hasConceptScore W4385800132C197934379 @default.
• W4385800132 hasConceptScore W4385800132C203014093 @default.
• W4385800132 hasConceptScore W4385800132C22070199 @default.
• W4385800132 hasConceptScore W4385800132C2777451964 @default.
• W4385800132 hasConceptScore W4385800132C2777704310 @default.
• W4385800132 hasConceptScore W4385800132C2780868878 @default.
• W4385800132 hasConceptScore W4385800132C32611913 @default.
• W4385800132 hasConceptScore W4385800132C535046627 @default.
• W4385800132 hasConceptScore W4385800132C71924100 @default.
• W4385800132 hasIssue "40" @default.
• W4385800132 hasLocation W43858001321 @default.

• next